High Pointe Capital Management’s Standard BioTools LAB Stock Holding History

High Pointe Capital Management’s Portfolio LAB Stock Details LAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-18,000	Closed	-$195K	–	105
2015 Q4	$195K	Hold	18,000	–	–	0.1%	155
2015 Q3	$146K	Sell	18,000 -15,590	-46%	-$245K	0.07%	166
2015 Q2	$813K	Sell	33,590 -270	-0.8%	-$8.52K	0.29%	131
2015 Q1	$1.43M	Sell	33,860 -7,570	-18%	-$299K	0.51%	83
2014 Q4	$1.4M	Sell	41,430 -5,020	-11%	-$142K	0.62%	73
2014 Q3	$1.14M	Hold	46,450	–	–	0.49%	90
2014 Q2	$1.37M	Buy	+46,450	New	+$1.49M	0.5%	97

Other funds holding LAB

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

LCS

Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return

CWAM

Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

RFC

Russell Frank Company Seattle, Washington $56.9B AUM 2.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

High Pointe Capital Management's LAB Position: Q1 2016 in Review

High Pointe Capital Management sold out of Standard BioTools (LAB) in Q1 2016, closing a stake of 18,000 shares — an estimated $195K sold.

High Pointe Capital Management first reported a position in LAB in Q2 2014 and held it in 7 quarters. The position peaked at $1.43M in Q1 2015. 100 funds tracked by Wall St. Rank hold LAB as of Q1 2016.

High Pointe Capital Management reported no remaining Standard BioTools position as of Q1 2016 after selling out during the quarter.
High Pointe Capital Management sold 18,000 Standard BioTools shares in Q1 2016, an estimated $195K.
High Pointe Capital Management first reported a position in Standard BioTools in Q2 2014 and held it in 7 quarters.
High Pointe Capital Management's Standard BioTools position peaked at $1.43M in Q1 2015.
100 funds tracked by Wall St. Rank held Standard BioTools as of Q1 2016.

Based on High Pointe Capital Management's 13F filing for Q1 2016, filed 5 May 2016.